Interesting T2DM: Diabetic Retinopathy & Drug News
Our February list includes a newly approved drug combo, the ADA’s position statement on diabetic retinopathy, and lifestyle intervention studies.
We present a selection of interesting news and research for the month of March focusing on type 2 diabetes. See the slide legends for links to the article summaries.Â
Interesting Type 2 Diabetes: Diabetic Retinopathy & Drug News. March 2017
Fracture Risk After Bariatric Surgery: Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding. Abstract link. ****Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. Abstract link.
Effects of Vildagliptin and Metformin on Blood Pressure and Heart Rate Responses to Small Intestinal Glucose in Type 2 Diabetes. Abstract Link. ********Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients with Chronic Heart Failure: Results from the ESC-HFA Heart Failure Long-Term Registry. Abstract Link.
CD40 in Retinal Müller Cells Induces P2X7-Dependent Cytokine Expression in Macrophages/Microglia in Diabetic Mice and Development of Early Experimental Diabetic Retinopathy. Abstract link. ****Diabetic Retinopathy: a Position Statement by the American Diabetes Association. Abstract link.
Low Gluten Diets May Be Associated with Higher Risk of Type 2 Diabetes. Press release.****3 Years of Liraglutide versus Placebo for Type 2 Diabetes Risk Reduction and Weight Management in Individuals with Prediabetes: a Randomised, Double-Blind Trial. Abstract link.
PREVENT-DM Comparative Effectiveness Trial of Lifestyle Intervention and Metformin. Abstract link. **** Effectiveness of Group-Based Self-Management Education for Individuals with Type 2 Diabetes: a Systematic Review with Meta-Analyses and Meta-Regression. Abstract link.
Effectiveness of mHealth Interventions for Patients with Diabetes: an Overview of Systematic Reviews. Abstract link.****Maintenance of Weight Loss After Initiation of Nutrition Training: a Randomized Trial. Abstract link.
FDA Approves Once-Daily Qtern (dapagliflozin and saxagliptin) Tablets for Adults with Type 2 Diabetes. Press release. ****Healthcare Resource Utilization and Related Financial Costs Associated with Glucose Lowering with Either Exenatide or Basal Insulin: a Retrospective Cohort Study. Abstract link.
Effect of Exercise Combined with Glucagon-Like Peptide-1 Receptor Agonist Treatment on Cardiac Function: a Randomised Double-Blinded Placebo-Controlled Clinical Trial. Abstract link. ****Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes. Press release.
Change in Percentages of Adults with Overweight or Obesity Trying to Lose Weight, 1988-2014. Abstract link. ****White Paper AGA: POWER - Practice Guide on Obesity and Weight Management, Education and Resources. Abstract Link.
